E arly revascularization with either fibrinolysis or primary percutaneous coronary intervention (PPCI) has been shown to improve survival in patients with ST-segment-elevation myocardial infarction (STEMI). 1-3 Multiple randomized trials have demonstrated that in patients with STEMI presenting to community hospitals, rapid transfer to a PPCIcapable center improves outcomes compared with immediate fibrinolysis. [4] [5] [6] [7] The broad applicability of these findings has been questioned because of an average transfer delay of only 69 minutes across all trials and the low rates of rescue PCI and subsequent revascularization in the fibrinolysis arms. 8 Nonetheless, regional revascularization systems of care that forego immediate fibrinolysis and transfer patients with STEMI presenting to community hospitals to PPCIcapable hospitals have emerged worldwide.
for patients with PPCI with STEMI presenting to a non-PPCI capable site is currently lacking. Since PCI center doorto-balloon times have improved, it may be particularly important to focus on the overall transfer process from arrival at the non-PCI-capable center to arrival at the PCI center. 15 Accordingly, in a secondary analysis of the largest randomized controlled trial of patients with STEMI undergoing PPCI, we sought to examine the outcomes associated with door 1-to-door 2 (D1D2) times in patients undergoing interhospital transfer for PPCI. We prospectively selected D1D2 time and not door in to door out (DiDo) or first door-to-balloon time, as a transfer-delay measure for 2 reasons. First, DiDo does not account for delays in transportation itself. Second, we hypothesized that most of the variability in first door-to-balloon time will be described by the D1D2 time, since the PCI center arrival-to-balloon times would be consistently short.
Methods
The APEX-AMI trial was a multicenter, randomized, double-blind, placebo-controlled study, evaluating the potential role of pexelizumab (a humanized monoclonal antibody C5 complement inhibitor) in patients with STEMI undergoing PPCI. The trial enrolled 5745 patients with STEMI treated with PPCI at 296 sites in 17 countries. 16, 17 Patients >18 years of age were eligible if they presented within 6 hours of symptoms onset, PPCI was the planned reperfusion strategy, and they had 1 of 3 high-risk ECG characteristics (≥ 2 mm STsegment elevation in 2 anterior lateral leads or ≥ 2 mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total of ≥8 mm or a new left bundle branch block with at least 1 mm concordant ST elevation). Patients were enrolled and randomized at PCI centers, regardless of whether they presented directly to the PCI centers or were transferred from non-PCI centers. The Institutional Review Board of each participating hospital approved the protocol, and patients were required to provide written informed consent.
Transfer Groups and Time Intervals
The overall trial population was divided into 2 groups: a nontransfer group, composed of patients who presented to PPCI centers; and the transfer group, comprised of patients who initially presented to non-PCI-capable hospitals and underwent interhospital transfer to a PCI-capable center. Since no treatment effect with pexelizumab was observed, patients were not stratified further according to study drug assignment.
All time intervals were calculated from times entered into individual case report forms by local study personnel. Time intervals are shown in Figure 1 . Symptom-to-presentation time was defined as symptom onset to first hospital arrival; door 1-to-door 2 (D1D2) time (for transferred patients) was defined as arrival at the first hospital to arrival at the PCI-capable hospital; door in-to-door out time (for transferred patients) was defined as arrival to departure from non-PCI-capable hospital; transportation time (for transferred patients) was defined as departure from non-PCI hospital to arrival at PPCI hospital; PCI center arrival to balloon time (for transferred patients) was defined as PCI-center arrival to balloon inflation time; and first door-to-balloon time was defined as time from first hospital arrival to balloon inflation time.
Outcomes
The main outcome in the transfer group was the 90-day composite of death, shock, and heart failure. Our primary analysis assessed the association between D1D2 time (as a continuous variable) in transferred patients and the 90-day composite outcome. Prespecified secondary analyses included post-PCI thrombolysis in myocardial infarction flow; sum ST-segment resolution; infarct size assessed by peak creatinine kinase, muscle and brain; and the individual components of the primary outcome.
In a planned analysis of the transfer group, outcomes stratified by symptom-to-presentation time, APEX baseline risk, and D1D2 time were explored. 18
Statistical Methods
Continuous variables are presented as medians with first and third quartiles and are compared between groups with Wilcoxon rank sum test. The Kruskal-Wallis test is used for comparing medians across 3 or more groups. Categorical variables are presented as percentages and compared across groups with the Pearson χ 2 test or the Fisher exact test when sample sizes are small. The correlation between D1D2 time and door-to-balloon time is tested with Spearman rank correlation test (r s ). A Cox proportional hazards model is used to assess the relationship between D1D2 time and the 90-day composite end point (death, shock, and heart failure) after multivariable adjustment. Since this model assumes that the covariates have a linear effect on the log-hazard, the Stone and Koo additive spline transformation is first applied to each covariate in an unadjusted model. 19 Covariates that exhibit significant nonlinearity are transformed with a linear spline, using both a grid search and graphical check for the optimal knot points. Two-piece linear splines are sufficient for the nonlinear covariates, age (knot at 55 years), baseline heart rate (knot at 70 bpm), D1D2 time (knot at 150 minutes), and baseline creatinine (knot at 0.9 mg/dL). Multiple imputations are performed to avoid using a complete-case analysis. Multiple imputations assume a multivariate normal distribution for the covariates. The continuous covariates are approximately normally distributed within the given range for imputed values and values for the binary baseline Q-wave covariate are imputed with no rounding. Five imputed data sets are generated with PROC MI, and the final adjusted model is given using PROC MIANALYZE. The proportional hazards c-indices for each imputed model and the final model are all 0.83. The proportional hazards assumption is verified graphically by plotting the Schoenfeld residuals against log (time)
WHAT IS KNOWN?
• Randomized trials have found that rapid transfer of patients with STEMI to PPCI-capable centers improves outcomes compared with immediate fibrinolysis. • Observational studies have shown that only a fraction of patients undergoing interhospital transfer for PPCI in the United States meet guideline-recommended door-to-balloon times and that delays in portions of the transfer process (eg, DiDo time in transfer hospital) are associated with increased mortality.
WHAT THIS STUDY ADDS?
• This study used an integrated measure of interhospital transfer delay, D1D2 time, which incorporates both presenting hospital and transportation delays. • Longer D1D2 times were associated with a higher incidence of death, shock, and heart failure at 90 days, although the association was no longer significant after multivariable adjustment. • Lack of an independent association of the interhospital transfer delays observed within the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial may have been, at least in part, owing to the relatively short delays compared with other controlled trials and observational registries.
for each covariate. In a planned secondary analysis, D1D2 times were stratified according to APEX risk score tertiles. This risk score uses baseline variables to predict 90-day mortality and has good discriminative properties (c=0.821). 18 All analyses are performed in SAS v9.2 (SAS Institute). The significance level is set at 0.05.
Results

Study Population
Among the 5745 patients in the APEX-AMI trial, 2075 (36.1%) patients were transferred from the presenting hospital for PPCI. Transfer status was not available in 3 patients. Compared to nontransferred patients, those undergoing transfer for PPCI were more likely to have prior coronary artery disease, higher heart rate, and lower serum creatinine ( Table 1) . The median symptom-to-presentation time was longer in the nontransferred group (101 versus 82 minutes; P < 0.001). The symptom onset-to-balloon time (229 versus 184; P< 0.001) and first door-to-balloon time (132 versus 76 minutes; P< 0.001) were longer in the transferred group. The percentage of patients achieving first door-to-balloon times < 90 minutes was 66% in the nontransferred and 19% in the transferred groups. First door-to-balloon times were highly correlated with D1D2 times in transferred patients (r s = 0.816; P< 0.001). In transferred patients, the median D1D2 time was 84 minutes. The median PCI center arrival-to-balloon time in transferred patients was significantly shorter than the nontransferred patients' time (45 versus 76 minutes; P< 0.001) minutes. On arrival at the PCI center, ~half of the patients were treated between 30 to 60 minutes, and 85.5% were treated in < 75 minutes.
Several regional differences were observed. The largest proportion of transferred patients was in Western Europe. First door-to-balloon times < 90 minutes among transferred patients was achieved in 23.9% of Western European patients, 20.8% from Australian and New Zealand, 18.5% from North America, and 14.2% from Eastern Europe.
D1D2 Time
Selected baseline characteristics stratified by D1D2 time are shown in Table 2 . Patients with longer D1D2 times tended to be female, have more comorbidities, anterior infarctions, higher heart rates, shorter symptom-to-presentation times, and were more likely to present on weekday evenings.
Outcomes
The 90-day primary outcome in the transfer and no transfer groups were 10.3% and 10.2%, respectively (P = 0.89). Outcomes stratified by D1D2 times are presented in Table 3 and Figure 2 . Significant nonlinearity at 150 minutes was observed between D1D2 time as a continuous variable and the primary outcome, with a less steep relationship beyond 150 minutes, thus D1D2 was analyzed as a spline in the unadjusted and adjusted model. The 90-day incidence of death, shock, and heart failure was higher for patients with a D1D2 times ≤150 minutes (hazard ratio, 1.19 per 30 minutes; 95% confidence interval, 1.06 to 1.33; P = 0.004) but not with D1D2 times >150 minutes (hazard ratio, 0.99; 95% confidence interval, 0.96 to 1.02; P = 0.496). A nonsignificant trend between heart failure and 90-day mortality was observed in patients with prolonged D1D2 times. No association was observed between D1D2 time and post-PCI thrombolysis in myocardial infarction flow, sum ST-segment recovery, or peak creatinine kinase, muscle and brain. The unadjusted primary outcome stratified by D1D2 time and symptom-to-presentation time (Figure 3a ) and APEX risk score tertiles (Figure 3b ) are shown. 18 Longer D1D2 times were associated with longer symptomto-presentation times (P< 0.001), but no association was observed between D1D2 times and APEX risk score tertiles (P = 0.176).
After multivariable adjustment, no significant association was observed between 90-day death, shock, or heart failure and either D1D2 time ≤150 minutes (adjusted HR, 1.07 per 30 minutes; 95% CI, 0.94 to 1.22; P = 0.291) or D1D2 time >150 minutes (adjusted HR, 0.98; 95% CI, 0.94 to 1.01; P = 0.196).
Discussion
There are 2 important findings in this analysis of a large PPCI trial population. First, unadjusted D1D2 time was strongly associated with 90-day outcomes in patients undergoing interhospital transfer for PPCI, although this relationship was not significant after multivariable adjustment. Second, the difference in symptom-to-balloon time between transferred and nontransferred patients was only 45 minutes. This analysis may lend insights into why some observational studies, but not this analysis or analyses from other randomized studies, have shown outcome differences associated with interhospital transfer delays.
Delays in STEMI revascularization are associated with increased mortality; however a meta-analysis of randomized controlled trials of patients with STEMI presenting at community hospitals showed that foregoing immediate thrombolysis in favor of transfer to a PPCI-capable center may improve outcomes. 7 The generalizability of these results have been questioned, given the small difference in treatment time (average, 69 minutes) and the low rates of rescue PCI and subsequent revascularization in the fibrinolysis arms. 8 Observational studies have reported that transfer delays are associated with higher mortality, and only a minority of patients are treated within guideline-recommended time frames; first door-to-balloon times are met in <1 in 5 US patients, and DIDO times are met in ~1 in 10. 9, 10, 12, 14 This study's finding that D1D2 time is not independently associated with 90-day death, shock, and heart failure supports the results of previous controlled studies; however, these results should not be extrapolated to imply superiority of mechanical revascularization over fibrinolysis for patients presenting to non-PCI-capable hospitals irrespective of transportation delays.
This analysis provides insights into the differences in outcomes associated with transfer for PPCI reported between controlled and observation studies. The difference in total ischemic time (symptom-to-balloon) was only 45 minutes between the transfer and nontransfer groups. This is small compared with the reported transfer delays of 48 to 111 minutes reported from previous controlled trials evaluating reperfusion strategies for patients presenting to non-PCI-capable hospitals. 8 Additionally, the transfer times achieved in this study are shorter to those in observational registry studies. In separate recent reports from the National Cardiovascular Data Registry and the Get With the Guidelines ACTION Registry, the median D1D2 time was 107 minutes, and the median DiDo time was 68 minutes, respectively. 9, 13 Both of these measures are longer than the median D1D2 time (84 minutes) and DiDo (43 minutes) achieved in this trial. This disparity highlights the fact that patients enrolled in clinical trials may not be representative of those in everyday clinical practice, and the results of our study should be interpreted accordingly. We hypothesize that the APEX-AMI trial may have included study centers with superior transfer systems or geographically smaller referral networks compared with the average PPCI center. In addition, patient randomization occurred at PPCI-capable centers and not at presenting hospitals, thus there is an inherent possibility that there was selective enrollment bias in favor of patients with shorter transfer times.
Our Results in Perspective
This study suggests that transfer of a patient with STEMI for PPCI is the preferred reperfusion strategy if it can be achieved in a timely fashion. The lack of an observed difference in 90-day outcomes between the transferred and nontransferred groups likely reflects that an 84-minute D1D2 time and 45-minute difference in total ischemic time likely is not associated with a substantially worse outcome. Nevertheless, it is our opinion that these findings should not be used to support a mechanical reperfusion-only strategy, as transfer times achieved within this trial may not be achievable in all healthcare regions. Guidelines underscore the importance of timely reperfusion, and there are calls for integrated regional PCI/fibrinolysis STEMI care systems. 20, 21 Acceptable transfer delays, however, remain undefined. European Society of Cardiology guidelines recommend a first medical contact-to-balloon time of < 2 hours, and a recent retrospective analysis has suggested the superiority of fibrinolysis when the PCI-related delay (door to balloon-door to needle time) exceeds 120 minutes, but prospective validation of this interval is lacking. 22, 23 Given the importance of timely reperfusion, regional systems of care should continue to try and minimize PPCI transfer delays until acceptable delays are prospectively defined.
D1D2 Time as a Measure of Transfer Delay
We explored D1D2 time as an interhospital transfer-delay measure encompassing both the presenting hospital DiDo time and the transportation time as a predictor of outcomes in patients transferred for PPCI. Although both DiDo and door-to-balloon times have been associated with mortality, we feel D1D2 time is the best integrated descriptor of interhospital transfer delays. DiDo times only reflect presenting hospital delays and do not account for transportation times. As demonstrated in this analysis, the PCI center arrival-to-balloon times in transferred patients were short, likely reflecting catheterization laboratory preactivation. Additionally, D1D2 was highly correlated with overall door-to-balloon time. Finally, the outcomes associated with symptom-to-balloon and first door-to-balloon times in the APEX-AMI trial, albeit not in transferred patients, have been previously published; however, these metrics were not the focus of this analysis. 3
Limitations
Three additional limitations merit consideration. The relationship between delay and outcome is complex, and it relates to both the effect of the delay itself, as well as the effect of measured and unmeasured confounders. Secondly, this study did not include a fibrinolysis arm, thus, comparison of reperfusion 
